Business Description
Virax Biolabs Group Ltd
ISIN : KYG9495L1251
Share Class Description:
VRAX: Class ATotal Employee Number:
26Description
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 15.52 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | -0.08 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -4.74 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -47.6 | |||||
3-Year EBITDA Growth Rate | 52.4 | |||||
3-Year EPS without NRI Growth Rate | 52.5 | |||||
3-Year FCF Growth Rate | 50.5 | |||||
3-Year Book Growth Rate | -55.4 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 59.42 | |||||
9-Day RSI | 55 | |||||
14-Day RSI | 50.76 | |||||
3-1 Month Momentum % | -49.28 | |||||
6-1 Month Momentum % | -27.14 | |||||
12-1 Month Momentum % | -79.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.97 | |||||
Quick Ratio | 9.97 | |||||
Cash Ratio | 9.4 | |||||
Days Inventory | 5556.11 | |||||
Days Sales Outstanding | 42.12 | |||||
Days Payable | 3041.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -110.6 | |||||
Shareholder Yield % | -3.53 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 53.85 | |||||
Operating Margin % | -49223.08 | |||||
Net Margin % | -38646.15 | |||||
EBITDA Margin % | -41776.92 | |||||
FCF Margin % | -37523.08 | |||||
OCF Margin % | -35553.85 | |||||
ROE % | -81.1 | |||||
ROA % | -73.64 | |||||
ROIC % | -288.89 | |||||
3-Year ROIIC % | 33.07 | |||||
ROC (Joel Greenblatt) % | -340.87 | |||||
ROCE % | -93.97 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 109.98 | |||||
PB Ratio | 0.24 | |||||
Price-to-Tangible-Book | 0.24 | |||||
EV-to-EBIT | 0.63 | |||||
EV-to-Forward-EBIT | 0.01 | |||||
EV-to-EBITDA | 0.69 | |||||
EV-to-Revenue | -286.54 | |||||
EV-to-Forward-Revenue | 1.29 | |||||
EV-to-FCF | 0.76 | |||||
Price-to-GF-Value | 0.89 | |||||
| Price-to-Net-Current-Asset-Value | 0.3 | |||||
| Price-to-Net-Cash | 0.33 | |||||
Earnings Yield (Greenblatt) % | 158.73 | |||||
FCF Yield % | -191.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VRAX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Virax Biolabs Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.013 | ||
| EPS (TTM) ($) | -16.886 | ||
| Beta | 1.4986 | ||
| 3-Year Sharpe Ratio | -0.16 | ||
| 3-Year Sortino Ratio | -0.4 | ||
| Volatility % | 73.81 | ||
| 14-Day RSI | 50.76 | ||
| 14-Day ATR ($) | 0.460163 | ||
| 20-Day SMA ($) | 2.92625 | ||
| 12-1 Month Momentum % | -79.06 | ||
| 52-Week Range ($) | 2.5 - 21.75 | ||
| Shares Outstanding (Mil) | 0.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Virax Biolabs Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Virax Biolabs Group Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-11-30 | In 100 days | ||
| First quarter earnings results for 2027 | 2026-08-31 | In 9 days | ||
| Annual report for 2026 | 2026-07-06 | 3.13 (+15.93%) | ||
| 0.04:1 Stock Split | 2026-06-26 | 3.38 (+0.00%) | ||
| General meeting for 2025 | 2026-03-18 13:00 | 5.07 (+4.70%) | ||
| Annual report for 2024 | 2025-08-20 | 19.38 (+0.34%) | ||
| Annual report for 2025 | 2025-07-02 | 21.00 (+6.82%) | ||
| General meeting for 2024 | 2024-12-12 13:00 | 42.50 (-3.41%) | ||
| 0.1:1 Stock Split | 2023-12-18 | 39.70 (-6.53%) |
Show
Entries
Virax Biolabs Group Ltd Frequently Asked Questions
What is Virax Biolabs Group Ltd(VRAX)'s stock price today?
The current price of VRAX is $3.20. The 52 week high of VRAX is $21.75 and 52 week low is $2.50.
When is next earnings date of Virax Biolabs Group Ltd(VRAX)?
The next earnings date of Virax Biolabs Group Ltd(VRAX) is 2026-08-31 Est..
Does Virax Biolabs Group Ltd(VRAX) pay dividends? If so, how much?
Virax Biolabs Group Ltd(VRAX) does not pay dividend.
Press Release
Articles on Virax Biolabs Group Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers